Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06333652 · ClinicalTrials.gov registry record · Phase 2
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
A Phase 2 study of Preeclampsia, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06333652: Recruiting Phase 2 study of Preeclampsia, sponsored by Mayo Clinic.
NCT06333652 is a Phase 2 study of Preeclampsia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 14 participants, below the 1,126-participant average among 48 other Preeclampsia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06333652, a Phase 2 study of Preeclampsia, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Primary Outcome
Concentration in serum of biomarkers: sMAC, Bb, and C5 at time of delivery
Conditions Studied
Interventions
- DRUG Ravulizumab
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT06333652 shows while recruiting
NCT06333652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,126-participant average among 48 other Preeclampsia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.
NCT06333652 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06333652 about?
NCT06333652 is a clinical study titled "Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders". The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
What is the current status of trial NCT06333652?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-03-01. Estimated completion is 2028-12-31.
What conditions does trial NCT06333652 study?
This clinical trial studies the following conditions: Preeclampsia.
What interventions are being tested in trial NCT06333652?
The interventions under investigation include: Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT06333652?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06333652 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06333652's enrollment target sits among peer trials
14 49th of 48 the lowest of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy